FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT	OF	CHANGES	IN RI	ENFFIC.	ΙΔΙ	OWNERSHII	P
	♥.			,		CITILLICI	

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* McCombe William D.					2. Issuer Name and Ticker or Trading Symbol <u>Cytek Biosciences, Inc.</u> [CTKB]							(Che	elationship o eck all applica Director	able)	g Perso	on(s) to Issu 10% Ow Other (s	ner		
(Last)	`	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/13/2024						below)	nief Fina	ncial	below)	респу			
47215 L	AKEVIEW	BOULEVARD			4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) FREMO	NT C	A	94538												ed by Mor		rting Person One Report		
(City)	City) (State) (Zip) Rule 10b5-1(c) T							Transa	acti	on Ind	ication								
							Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Та	ble I - Non	-Deriv	/ativ	/e Se	curities	s Ac	quired,	Dis	posed c	of, or Be	neficially	/ Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,		Code (I	Transaction Dispose Code (Instr.		rities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amoun Securities Beneficia Owned Fo	s lly ollowing	Form: (D) or	: Direct II Indirect E str. 4) (7. Nature of ndirect Beneficial Dwnership Instr. 4)			
								Code	v	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	ion(s)			mstr. 4)		
			Table II - D						uired, D s, option					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Co	ransaction ode (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				C	ode	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	on(3)			
Employee Stock Option (right to buy)	\$6.18	05/13/2024			A		150,602		(1)	0	5/13/2034	Common Stock	150,602	\$0	150,60	02	D		
Restricted Stock Units	(2)	05/13/2024			A		101,132		(3)		(3)	Common Stock	101,132	\$0	101,13	32	D		

Explanation of Responses:

- 1. The shares subject to the option shall vest over 4 years with 25% of the total shares underlying the option vesting on May 13, 2025 and 1/48th of the total shares subject to the option vesting each month thereafter.
- $2. \ Each \ Restricted \ Stock \ Unit \ (the \ "RSU \ Award") \ represents \ a \ contingent \ right to \ receive \ one \ share \ of the \ Issuer's \ common \ stock.$
- 3. The shares subject to the RSU Award shall vest over 4 years with 12/48 of the total shares underlying the RSU Award vesting on May 18, 2025; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 3/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each March 10, 2026 and each March 10 thereafter; and 3/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter.

/s/ Valerie Barnett, Attorney-in-Fact 05/15/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.